LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Accueil・Liste d'Actions・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fermé

SecteurSoins de santé

10.6 -7.75

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.6

Max

11.49

Chiffres clés
By Trading Economics
Revenu	227M
Ventes	139M
P/E Moyenne du Secteur	4.302 49.888
Marge bénéficiaire	163.843
Employés	1,796
EBITDA	1.3M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+45.83% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2B
Ouverture précédente	18.35
Clôture précédente	10.6

Sentiment de l'Actualité

By Acuity

10%

90%

9 / 344 Classement par Healthcare

Hutchison China MediTech Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juin 2026, 23:22 UTC

Résultats

Principaux Mouvements du Marché

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 juin 2026, 23:09 UTC

Actions en Tendance

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 juin 2026, 20:51 UTC

Résultats

Costco Reports 15% Sales Growth in May

3 juin 2026, 20:43 UTC

Résultats

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 juin 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 juin 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juin 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 juin 2026, 23:15 UTC

Market Talk

Résultats

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 juin 2026, 22:08 UTC

Actions en Tendance

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 juin 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 juin 2026, 21:18 UTC

Résultats

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 juin 2026, 21:15 UTC

Résultats

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 juin 2026, 21:13 UTC

Résultats

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 juin 2026, 21:13 UTC

Résultats

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 juin 2026, 21:12 UTC

Résultats

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 juin 2026, 21:09 UTC

Résultats

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 juin 2026, 21:03 UTC

Résultats

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 juin 2026, 20:43 UTC

Résultats

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 juin 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 juin 2026, 20:37 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 juin 2026, 20:35 UTC

Résultats

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 juin 2026, 20:17 UTC

Résultats

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 juin 2026, 20:17 UTC

Résultats

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Adj EPS $2.44 >AVGO

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q EPS $1.91 >AVGO

3 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Rev $22.19B >AVGO

Comparaison

Variation de prix

Hutchison China MediTech Ltd ADR prévision

Objectif de Prix

By TipRanks

45.83% hausse

Prévisions sur 12 Mois

Moyen 16.8 USD 45.83%

Haut 20 USD

Bas 13.6 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

9 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.